AR044931A1 - Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas - Google Patents

Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas

Info

Publication number
AR044931A1
AR044931A1 ARP040102258A ARP040102258A AR044931A1 AR 044931 A1 AR044931 A1 AR 044931A1 AR P040102258 A ARP040102258 A AR P040102258A AR P040102258 A ARP040102258 A AR P040102258A AR 044931 A1 AR044931 A1 AR 044931A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
aryl
sulfonylmetilalquil
hydroxiformamids
Prior art date
Application number
ARP040102258A
Other languages
English (en)
Inventor
Raymond Maurice Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044931A1 publication Critical patent/AR044931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de piperazina o su sal, prodroga o solvato aceptable para uso farmacéutico. Procesos para su preparación, composiciones farmacéuticas que los contienen y su uso con fines terapéuticos. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) o una sal, prodroga o solvato aceptable para uso farmacéutico del mismo, donde el anillo B representa un anillo monocíclico que contiene seis átomos en el anillo o un anillo heteroarilo monocíclico que tiene hasta seis átomos en el anillo y que contiene uno o más heteroátomos en el mismo, donde cada uno de estos heteroátomos es N; R2 representa un grupo seleccionado entre C1-6-alquilo o arilo, donde dicho grupo está sustituido por uno o más grupos que contienen F; n es 1, 2, o 3; y R1 representa un grupo sustituido opcionalmente seleccionado entre C1-6-alquilo, C5-7-cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C1-6-alquil-arilo, C1-6-alquil-heteroarilo, C1-6-alquil-cicloalquilo o C1-6-alquil-heterocicloalquilo.
ARP040102258A 2003-06-27 2004-06-25 Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas AR044931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
AR044931A1 true AR044931A1 (es) 2005-10-12

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102258A AR044931A1 (es) 2003-06-27 2004-06-25 Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas

Country Status (34)

Country Link
US (1) US7485644B2 (es)
EP (1) EP1644340B1 (es)
JP (1) JP4701167B2 (es)
KR (1) KR20060026440A (es)
CN (2) CN102229589A (es)
AR (1) AR044931A1 (es)
AT (1) ATE414063T1 (es)
AU (1) AU2004251104B2 (es)
BR (1) BRPI0411929A (es)
CA (1) CA2529468A1 (es)
CO (1) CO5650254A2 (es)
CY (1) CY1108757T1 (es)
DE (1) DE602004017733D1 (es)
DK (1) DK1644340T3 (es)
ES (1) ES2315675T3 (es)
HK (1) HK1086835A1 (es)
HR (1) HRP20090009T3 (es)
IL (1) IL172615A0 (es)
IS (1) IS8257A (es)
MX (1) MXPA05013460A (es)
MY (1) MY138680A (es)
NO (1) NO20060444L (es)
NZ (1) NZ544208A (es)
PL (1) PL1644340T3 (es)
PT (1) PT1644340E (es)
RU (1) RU2351595C2 (es)
SA (1) SA04250224B1 (es)
SE (1) SE0301922D0 (es)
SI (1) SI1644340T1 (es)
TW (1) TW200524898A (es)
UA (1) UA81491C2 (es)
UY (1) UY28387A1 (es)
WO (1) WO2005000822A1 (es)
ZA (1) ZA200510458B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CA2804918C (en) * 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735929B2 (en) * 1998-01-30 2001-07-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
NZ515829A (en) * 1999-06-04 2003-10-31 Astrazeneca Ab Inhibitors of metalloproteinases
RU2283306C2 (ru) 2000-02-21 2006-09-10 Астразенека Аб Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003091247A2 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2528317A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
SI1644340T1 (sl) 2009-02-28
AU2004251104B2 (en) 2008-05-08
PT1644340E (pt) 2009-01-02
HRP20090009T3 (en) 2009-02-28
KR20060026440A (ko) 2006-03-23
IS8257A (is) 2006-01-23
EP1644340B1 (en) 2008-11-12
US20070197542A1 (en) 2007-08-23
CY1108757T1 (el) 2014-04-09
UY28387A1 (es) 2005-01-31
RU2005141058A (ru) 2006-07-27
CN1812974B (zh) 2011-06-29
DK1644340T3 (da) 2009-02-02
RU2351595C2 (ru) 2009-04-10
JP2007516164A (ja) 2007-06-21
US7485644B2 (en) 2009-02-03
TW200524898A (en) 2005-08-01
ATE414063T1 (de) 2008-11-15
CN1812974A (zh) 2006-08-02
DE602004017733D1 (de) 2008-12-24
WO2005000822A1 (en) 2005-01-06
CA2529468A1 (en) 2005-01-06
ES2315675T3 (es) 2009-04-01
CN102229589A (zh) 2011-11-02
IL172615A0 (en) 2006-04-10
SE0301922D0 (sv) 2003-06-27
EP1644340A1 (en) 2006-04-12
BRPI0411929A (pt) 2006-08-15
CO5650254A2 (es) 2006-06-30
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
MXPA05013460A (es) 2006-03-09
MY138680A (en) 2009-07-31
HK1086835A1 (en) 2006-09-29
PL1644340T3 (pl) 2009-04-30
ZA200510458B (en) 2007-03-28
UA81491C2 (en) 2008-01-10
NO20060444L (no) 2006-03-22
JP4701167B2 (ja) 2011-06-15
AU2004251104A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20221905A1 (es) Aminas biciclicas como inhibidoras de la cdk2
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR097325A1 (es) Pirroles anillados
CL2008001669A1 (es) Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR050963A1 (es) Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres.
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
PE20240886A1 (es) Compuestos espirociclicos
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR064488A1 (es) DERIVADOS DE4-(1-AMINO-ETIL)-CICLOHEXILAMINA, UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE Y EL USO DE LOS MISMOS PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE UNA INFECCION BACTERIANA
AR046753A1 (es) Derivados de benzoxazina y usos de los mismos
AR044931A1 (es) Compuestos de n-{'4-piperazina sustituida -1-sulfonilmetilalquil}-n-hidroxiformamidas como inhibidores de metaloproteasas
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
AR042887A1 (es) Derivados de diarilmetiden piperidina preparaciones y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal